Viking (VKTX) Q4 2025 earnings review
Flawless Clinical Execution at the Cost of Accelerating R&D Burn
As a pre-revenue clinical-stage biotech, Viking's narrative is entirely driven by pipeline execution and cash runway. The company delivered on all fronts: VANQUISH-1 Phase 3 enrollment finished ahead of schedule, oral VK2735 is advancing to Phase 3, and a novel amylin agonist is entering the clinic. However, this rapid progress comes with a massive price tag. R&D expenses accelerated violently, surging 395% YoY to $153.5M in Q4, driving a net loss of $1.38 per share. Despite the heavy spending, Viking's fortress balance sheet of $706M provides ample runway to reach critical Phase 3 data readouts without an immediate need for dilutive financing.
🐂 Bull Case
Viking is successfully advancing both subcutaneous and oral formulations of VK2735 into Phase 3 trials, creating a flexible, multi-billion dollar commercial opportunity using the exact same active molecule.
With $706M in cash and short-term investments, management confirmed they are fully funded through the completion of the subcutaneous Phase 3 trials and the readouts for the upcoming oral Phase 3.
🐻 Bear Case
Viking will eventually launch against well-entrenched incumbents (Lilly, Novo) who possess massive cardiovascular outcomes data—a major hurdle for broad payer reimbursement.
The simultaneous execution of multiple mega-trials has caused cash burn to spike. R&D spending quintupled YoY in Q4, creating a tighter margin for error in pipeline execution.
⚖️ Verdict: 🟢
Bullish. The aggressive acceleration in R&D spend is the necessary cost of playing in the obesity mega-market. Viking is moving with unprecedented speed, and its pipeline depth provides a strong foundation.
Key Themes
Subcutaneous and Oral Formulations Powering Phase 3 Expansion
Viking's primary value driver is the VK2735 franchise. Following impressive Phase 2 weight loss (up to 14.7% for subQ; 12.2% for oral), the subQ VANQUISH-1 trial (~4,500 patients) is fully enrolled ahead of schedule. Crucially, following an FDA meeting, Viking will advance the oral formulation directly into a Phase 3 program in 26Q3. Using the same dual GLP-1/GIP agonist for both forms mitigates transition side effects, offering a seamless patient journey.
Pioneering Flexible Maintenance Dosing
To address payer concerns regarding long-term persistence, Viking initiated a unique Phase 1 maintenance study. After 19 weeks of weekly subQ dosing, patients transition to monthly subQ, weekly oral, or daily oral regimens. Demonstrating stable weight maintenance on a monthly or weekly basis would be a massive commercial differentiator. Data is expected in 3Q26.
Pipeline Depth: Advancing Novel Amylin Agonist (DACRA)
Viking is reducing reliance on the GLP-1 mechanism by preparing an Investigational New Drug (IND) application in 1Q26 for a dual amylin and calcitonin receptor agonist (DACRA). Early primate data suggests it is highly potent. This provides a critical next-generation asset that could be used as a monotherapy for GLP-1 intolerant patients or in combination therapies.
Exploding R&D Run-Rate vs Guided Burn
A clear contradiction exists between Q4 data and forward guidance. Q4 R&D expenses hit an unprecedented $153.5M, but management guided for a go-forward quarterly cash usage of only $60M-$90M. This implies Q4 contained massive non-cash stock compensation or heavy one-time clinical pre-payments (likely related to the CordenPharma manufacturing deal). Regardless, the overall trajectory is steeply accelerating.
Lack of Outcomes Data is a Payer Risk
The macro environment for obesity drugs is shifting toward demanding cardiovascular and metabolic outcomes data for broad payer reimbursement. Incumbents have a multi-year head start on these massive outcomes trials. When asked about this on the call, management largely sidestepped the issue, indicating they are focused on the primary weight-loss indications first.
Undefined Go-To-Market Strategy
The rapid evolution of the obesity market—specifically the rise of telehealth compounders (e.g., Hims, Ro)—presents a shifting macro landscape. While Viking recently hired a Chief Commercial Officer (Neil Aubuchon), the company admits it is starting from a 'blank slate' and evaluating whether to partner with big pharma, leverage telehealth channels, or go it alone. This strategic ambiguity presents long-term execution risk.
Other KPIs
Decelerating slightly from $903M at the end of 2024, but representing a fortress balance sheet for a clinical-stage biotech. The burn rate is manageable, and management confirmed this capital is sufficient to cross the finish line for the ongoing subcutaneous Phase 3 trials and fund the oral Phase 3 program to top-line data.
Accelerating violently. Up 239% from $101.6M in 2024. This reflects the immense capital intensity of running two massive 78-week Phase 3 obesity trials (~5,600 total patients) simultaneously, alongside manufacturing scale-up initiatives.
Guidance
Decelerating. The CFO explicitly stated that future cash burn will range between $60M and $90M per quarter. This is a sharp drop from the $153.5M total R&D expense recognized in Q4, indicating that Q4 included significant one-time prepayments or non-cash charges.
Stable timeline following a positive end-of-Phase 2 meeting with the FDA. This trial is expected to be smaller and shorter in duration than the subcutaneous VANQUISH trials.
The Phase 1 maintenance study is fully enrolled, with readouts on weekly oral and monthly subcutaneous dosing schedules expected in the third quarter of 2026.
Accelerating progress. Following the early completion of VANQUISH-1, the 1,100-patient trial evaluating VK2735 in obese patients with Type 2 Diabetes is expected to finish enrolling this quarter.
Key Questions
Bridging the Q4 R&D vs Cash Burn Gap
With Q4 R&D hitting $153M but guided forward cash usage at $60M-$90M, how much of the Q4 expense was driven by non-cash stock compensation versus upfront clinical/manufacturing milestone payments?
Cardiovascular Outcomes Strategy
Given that competitors are successfully utilizing cardiovascular outcomes data to secure broader payer coverage and Medicare reimbursement, what is Viking's long-term strategy for generating outcomes data?
Commercial Partnership Appetite
With the oral formulation advancing to Phase 3, does management feel pressure to secure a global commercialization partner prior to the data readout, or are you fully prepared to build an independent sales infrastructure?